2 patents currently held
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2033. from the record
Of the 26 now held by other companies, 16 name Agilent Technologies Inc. as their current owner, and 10 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2033
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Mar 2033 · Medium confidence
Also notable
Ends Jul 2034 · High confidence
Novel Egfr Modulators and Uses Thereof
US 10,449,196
A family of 8 related applications built on the 2019 grant. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Heterocyclic Compounds and Uses Thereof
US 10,562,918
Granted 2020. Computed term ends 2034. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends no later than Mar 2031 · Medium confidence
Cited by 48 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Agilent Technologies, Inc.
Also notable
Ends Feb 2033 · High confidence
Cited by 55 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
now held by Agilent Technologies, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 22, 2027The maintenance fee for Novel Egfr Modulators and Uses Thereof (US 10,449,196) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Heterocyclic Compounds and Uses Thereof (US 10,562,918) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heterocyclic Compounds and Uses Thereof | 1 in force | to Jul 2034 |
| Novel Egfr Modulators and Uses Thereof | 1 in force | to Mar 2033 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,449,196 | Novel Egfr Modulators and Uses Thereof held by Acea Therapeutics, Inc. In force · Medium confidence | In force | Medium confidence | |
| US 10,562,918 | Heterocyclic Compounds and Uses Thereof held by Acea Therapeutics, Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 26 patents in force now held by others · 30 patents ended · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
8 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed